Epinastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H15N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q13WX941EF, chemically known as 3-amino-9,13b-dihydro-1h-dibenz(c,f)imidazo(1,5-a)azepine but generally known as epinastine, which bears US NIH Compound Identifier 3241. European Medicines Agency schedules Epinastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06567MIG. The term EPINASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). World Health Organization schedules epinastine in its Anatomical Therapeutic Chemical (ATC) Classification. EPINASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule epinastine under HS 29339930 and SITC 51577. As of Q4 2014, EPINASTINE remains the US FDA Preferred Term for this commodity. Epinastine bears US NLM identifiers UMLS ID C0078442 and NCI Concept Code C65515. SMILES: N12C(C3C(CC4C1CCCC4)CCCC3)CN=C2N.